Comments A 40-year-old man presented to the ICU after intubation due to respiratory failure secondary to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonitis. Past medical history revealed a history of intravenous drug use (heroin). Early blood and sputum cultures also grew a Panton-Valentine leukocidin–positive Staphylococcus aureus. Dexamethasone and antibiotics were administered and lung-protective ventilation and proning were instituted. Imaging during the first and second week of illness revealed rapid progression from pneumonitis to severe cystic bronchiectasis (Figures 1–3). The patient developed persistent hypercapnic acidosis, despite high Ve. Bedside calculations revealed dead space ventilation ranging from 5.14 L/min to 5.92 L/min. The patient received a tracheostomy in his third week of stay to facilitate weaning of mechanical ventilation. After ICU discharge, he received rehabilitation for critical illness myopathy and developed a mild persistent productive cough. He was discharged to a step-down facility for ongoing rehabilitation 5 months after admission.
Figure 1. Axial image from a computed tomography pulmonary angiogram demonstrates bilateral ground-glass opacification and consolidation, typical imaging features of coronavirus disease (COVID-19) pneumonitis. The bronchi are normal caliber.
[More] [Minimize]
Figure 2. Axial image from a contrast-enhanced computed tomography thorax 6 days later demonstrates new cystic dilation of the lobar, segmental, and subsegmental bronchi.
[More] [Minimize]
Figure 3. Axial image from a contrast-enhanced computed tomography thorax 7 days later demonstrates further progression of severe cystic bronchiectasis.
[More] [Minimize]Bronchiectasis is characterized by abnormal bronchial wall thickening and luminal dilation due to a cycle of infection and inflammation (1). Its development is a known complication of severe respiratory infection and is a reported complication of SARS-CoV-2, found in up to 11% of cases (2–5). The long-term sequelae of SARS-CoV-2 pneumonitis have yet to be fully elucidated. However, a number of authors have highlighted the potential for postinfective bronchiectasis to be an important issue (6, 7). This case is unusual for its rapid progression and highlights the association between SARS-CoV-2 and the development of bronchiectasis, particularly in the setting of Panton-Valentine leukocidin–positive S. aureus coinfection.
| 1. | Palange P, Simonds A. ERS handbook: respiratory medicine, 2nd ed. Wakefield, UK: Charlesworth Press; 2013. |
| 2. | Salehi S, Abedi A, Balakrishnan S, Gholamrezanezhad A. Coronavirus disease 2019 (COVID-19): a systematic review of imaging findings in 919 patients. AJR Am J Roentgenol 2020; 215:87–93. |
| 3. | Shi H, Han X, Jiang N, Cao Y, Alwalid O, Gu J, et al. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. Lancet Infect Dis 2020;20:425–434. |
| 4. | Ambrosetti MC, Battocchio G, Zamboni GA, Fava C, Tacconelli E, Mansueto G. Rapid onset of bronchiectasis in COVID-19 Pneumonia: two cases studied with CT. Radiol Case Rep 2020;15:2098–2103. |
| 5. | Fang Y, Zhang H, Xu Y, Xie J, Pang P, Ji W. CT manifestations of two cases of 2019 novel coronavirus (2019-nCoV) pneumonia. Radiology 2020;295:208–209. |
| 6. | José RJ, Manuel A, Gibson-Bailey K, Lee L. Post COVID-19 bronchiectasis: a potential epidemic within a pandemic. Expert Rev Respir Med 2020;14:1183–1184. |
| 7. | Fraser E. Long term respiratory complications of covid-19. BMJ 2020;370:m3001. |
*Lead author.
Originally Published in Press as DOI: 10.1164/rccm.202103-0642IM on January 4, 2022
Author disclosures are available with the text of this article at www.atsjournals.org.
